Drugs for Phelan-Mcdermid Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 48)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Celiprolol |
Approved, Investigational |
Phase 4 |
|
56980-93-9 |
|
Synonyms:
RS)-N'-{3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-N,N-diethylurea
|
|
|
2 |
|
Sympathomimetics |
|
Phase 4 |
|
|
|
3 |
|
Antihypertensive Agents |
|
Phase 4 |
|
|
|
4 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
5 |
|
Adrenergic beta-1 Receptor Antagonists |
|
Phase 4 |
|
|
|
6 |
|
Adrenergic beta-Antagonists |
|
Phase 4 |
|
|
|
7 |
|
Peripheral Nervous System Agents |
|
Phase 4 |
|
|
|
8 |
|
Adrenergic Antagonists |
|
Phase 4 |
|
|
|
9 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
10 |
|
Anti-Arrhythmia Agents |
|
Phase 4 |
|
|
|
11 |
|
Vasodilator Agents |
|
Phase 4 |
|
|
|
12 |
|
Autonomic Agents |
|
Phase 4 |
|
|
|
13 |
|
Sulfamethoxazole |
Approved |
Phase 2 |
|
723-46-6 |
5329
|
Synonyms:
129378-89-8
3-(P-Aminobenzenesulfonamido)-5-methylisoxazole
3-(p-Aminophenylsulfonamido)-5-methylisoxazole
3-(P-Aminophenylsulfonamido)-5-methylisoxazole
3-(P-Aminophenylsulphonamido)-5-methylisoxazole
3-(para-Aminophenylsulphonamido)-5-methylisoxazole
3-(Para-aminophenylsulphonamido)-5-methylisoxazole
3-Sulfanilamido-5-methylisoxazole
3-Sulphanilamido-5-methylisoxazole
46850_RIEDEL
4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide
4-amino-N-(5-Methyl-1,2-oxazol-3-yl)benzenesulfonamide
4-amino-N-(5-Methyl-3-isoxazolyl)benzenesulfonamide
4-amino-N-(5-Methyl-3-isoxazolyl)-benzenesulfonamide
4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide
4-amino-N-(5-Methyl-3-isoxazolyl)benzenesulphonamide
4-amino-N-(5-methylisoxazol-3-yl)benzenesulfonamide
4-Amino-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide
4-Amino-N-[5-methyl-3- isoxazolyl]benzenesulfonamide
5-Methyl-3-sulfanilamidoisoxazole
5-Methyl-3-sulfanylamidoisoxazole
5-Methyl-3-sulfonylamidoisoxazole
5-Methyl-3-sulphanil-amidoisoxazole
723-46-6
A047
AB00052099
AC-11118
AC1L1K42
AC1Q2J5R
AKOS000200952
ALBB-002089
Apo-Sulfamethoxazole
ARONIS018156
Azo Gantanol
azo-Gantanol
Azo-gantanol
Azo-Gantanol
Bactrim
Bactrimel
BAS 00836086
BB_SC-1251
BIDD:GT0731
BPBio1_000081
BRD-K28494619-001-05-0
BRN 0226453
BSPBio_000073
BSPBio_002028
C07315
C10H11N3O3S
CAS-723-46-6
CCRIS 567
CHEBI:9332
CHEMBL443
CID5329
CPD000058223
D00447
D013420
DB01015
DivK1c_000649
EINECS 211-963-3
Gamazole
Gantanol
Gantanol-DS
HMS1568D15
HMS1921A21
HMS2092K03
HMS502A11
HMS561O18
HSDB 3186
I01-0154
IDI1_000649
InChI=1/C10H11N3O3S/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h2-6H,11H2,1H3,(H,12,13)
KBio1_000649
KBio2_001474
KBio2_004042
KBio2_006610
KBio3_001528
KBioGR_000749
KBioSS_001474
LS-1620
Maybridge1_007190
Metoxal
MLS000069732
MLS001055354
MLS001074165
MolPort-000-145-787
MS 53
N'-(5-methyl-3-isoxazole)sulfanilamide
N'-(5-Methyl-3-isoxazole)sulfanilamide
|
N'-(5-methyl-3-isoxazolyl)sulfanilamide
N'-(5-methyl-3-isoxazolyl)-sulfanilamide
N'-(5-Methyl-3-isoxazolyl)sulfanilamide
N'-(5-methylisoxazol-3-yl)sulphanilamide
N'-(5-Methylisoxazol-3-yl)sulphanilamide
N(sup 1)-(5-Methyl-3-isoxazolyl)sulfanilamide
N(sup 1)-(5-Methyl-3-isoxazolyl)sulphanilamide
N(sup1)-(5-Methyl-3-isoxazolyl)sulfanilamide
N^1-(5-methyl-3-isoxazolyl)-sulfanilamide
N1-(5-Methyl-3-isoxazolyl)sulfanilamide
N1-(5-Methyl-3-isoxazolyl)-sulfanilamide
N1-(5-Methyl-3-isoxazolyl)sulphanilamide
N1-(5-Methylisoxazol-3-yl)sulfanilamide
NCGC00016533-01
NCGC00016533-02
NCGC00021995-03
NCGC00021995-04
NCGC00021995-05
nchembio.221-comp24
Ndimethyl1-(5-methyl-3-isoxazolyl)-sulfanilamide
NINDS_000649
NSC 147832
NSC147832
Oprea1_114486
Oprea1_285680
Prestwick_453
Prestwick0_000177
Prestwick1_000177
Prestwick2_000177
Prestwick3_000177
Radonil
Ro 4-2130
Ro 6-2580/11
Ro-4-2130
S0361
S1915_Selleck
S7507_FLUKA
S7507_SIGMA
SAM002554930
Septran
SIM
Simsinomin
Sinomin
SMR000058223
SMX
Solfametossazolo
Solfametossazolo [DCIT]
SPBio_000896
SPBio_001994
Spectrum_000994
SPECTRUM1500550
Spectrum2_000788
Spectrum3_000584
Spectrum4_000345
Spectrum5_000982
STK007988
Sulfamethalazole
Sulfamethoxazol
sulfamethoxazole
Sulfamethoxazole
SULFAMETHOXAZOLE (8064-90-2 (TRIMETHOPRIM/SULFAMETHOXAZOLE)
Sulfamethoxazole (JP15/USP/INN)
Sulfamethoxazole [USAN:INN:JAN]
Sulfamethoxazole sodium
Sulfamethoxazole(usan)
Sulfamethoxazolum
Sulfamethoxazolum [INN-Latin]
Sulfamethoxizole
Sulfamethylisoxazole
Sulfametoxazol
Sulfametoxazol [INN-Spanish]
Sulfanilamide, N1-(5-methyl-3-isoxazolyl)- (8CI)
Sulfisomezole
Sulphamethalazole
Sulphamethoxazol
Sulphamethoxazole
Sulphamethoxazole BP 98
Sulpha-methoxizole
Sulpha-Methoxizole
Sulphamethylisoxazole
Sulphisomezole
TL8005058
TMP/SMX (MIXTURE))
Trib
UNII-JE42381TNV
Urobak
WLN: T5NOJ C1 EMSWR DZ
ZINC00089763
|
|
14 |
|
Mecasermin |
Approved, Investigational |
Phase 2 |
|
68562-41-4 |
|
Synonyms:
Human somatomedin C
Mecasermin recombinant
|
Mecasermina
Mechano growth factor
|
|
15 |
|
Zinc |
Approved, Investigational |
Phase 2 |
|
7440-66-6 |
32051
|
Synonyms:
alpha D Mannosidase
alpha D Mannoside mannohydrolase
alpha Mannosidase
alpha Mannosidase b
alpha-D-Mannosidase
alpha-D-Mannoside mannohydrolase
alpha-Mannosidase
alpha-Mannosidase, lysosomal
alpha-Mannosidase, neutral
Dietary zinc
LAMAN
Lysosomal alpha mannosidase
Lysosomal alpha-mannosidase
Mannohydrolase, alpha-D-mannoside
|
Mannosidase b, alpha
Neutral alpha mannosidase
Neutral alpha-mannosidase
Topostin b
Zinc cation
ZINC ion
Zinc, chelated
Zinc, elemental
Zinc, ion (ZN2+)
Zincum metallicum
Zn
ZN(2+)
ZN(II)
ZN2+
|
|
16 |
|
Oxytocin |
Approved, Vet_approved |
Phase 2 |
|
50-56-6 |
439302
53477758
|
Synonyms:
(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
(Arg8)-vasopressin
(Arg8)-vasotocin
1-({(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-(4-hydroxybenzyl)-13-[(1S)-1-methylpropyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-L-leucylglycinamide
50-56-6
AC1L9735
alpha-Hypophamine
Argipressin
Argpressin acetate
BCBcMAP01_000094
Biotinyl-(arg8)-vasopressin
C00746
CHEBI:492195
CHEBI:7872
CHEMBL395429
CID439302
Cys-tyr-ile-GLN-asn-cys-pro-arg-gly-NH2
Cys-tyr-ile-GLN-asn-cys-pro-leu-gly-NH2
Cys-tyr-ile-THR-asn-cys-gly-leu-gly-NH2
Cys-tyr-phe-GLN-asn-cys-pro-arg-gly-NH2
Cys-tyr-phe-GLN-asn-cys-pro-lys-gly-NH2
D00089
Disulfide bridge cys1-cys6
Gly-leu-pro-c
HS-2021
L-Cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucylglycinamide cyclic(1-6)-disulfide
|
MolPort-003-938-941
NCGC00167132-01
nchembio.184-comp2
O3251_SIGMA
O4375_SIGMA
Ocytocin
Oxitocina
OXT
Oxytocic hormone
Oxytocin
OXYTOCIN
Oxytocin (JP15/USP/INN)
Oxytocin (TN)
Oxytocin 10 usp units in dextrose 5%
Oxytocin 20 usp units in dextrose 5%
Oxytocin 5 usp units in dextrose 5%
Oxytocin acetate
Oxytocin injection
Oxytocine
Oxytocinum
Pitocin
Pitocin (TN)
Syntocinon
Syntocinon (TN)
TI-001
|
|
17 |
|
Isotretinoin |
Approved |
Phase 2 |
|
4759-48-2 |
5282379
5538
|
Synonyms:
(13-cis)-Retinoate
(13cis)-retinoic acid
(13-cis)-Retinoic acid
(2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
(2Z,4E6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid
(7E,9E,11E,13Z)-Retinoate
(7E,9E,11E,13Z)-retinoic acid
(7E,9E,11E,13Z)-Retinoic acid
13 cis retinoic acid
13 cis Retinoic acid
13 Cis-Retinoic Acid
13-cis RA
13-cis retinoic acid
13-cis-Retinoate
13-cis-retinoic acid
13-cis-Retinoic acid
13-cis-Vitamin a acid
13-cis-Vitamin A acid
13-RA
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-cis-4-trans-6-trans-8-trans-nonatetraenoic acid
4-09-00-02388 (Beilstein Handbook Reference)
4759-48-2
97950-17-9
AC-15388
AC1NQZZ4
Accutane
Accutane (TN)
Ambap302-79-4
Amnesteem
BML2-E07
BPBio1_000080
BRD-K76723084-001-05-9
BRN 1885770
BSPBio_000072
BSPBio_001331
BSPBio_003345
CCRIS 4286
CHEBI:6067
CHEMBL547
CID5282379
CIP-isotretinoin
CIP-Isotretinoin
cis-RA
cis-Retinoate
cis-Retinoic acid
Claravis
CPD000471891
D00348
D015474
EINECS 225-296-0
EU-0101081
HMS1361C13
HMS1568D14
HMS1791C13
HMS1921D08
HMS1989C13
HMS2092N07
HSDB 3929
IDI1_033801
Isotane
|
Isotretinoin
Isotretinoin (USP)
Isotretinoin [USAN:INN:BAN]
Isotretinoin Retinoic acid
Isotretinoin zinc salt, 13 cis isomer
Isotretinoin Zinc Salt, 13 cis Isomer
Isotretinoin zinc salt, 13-cis-isomer
Isotretinoin Zinc Salt, 13-cis-Isomer
Isotretinoina
Isotretinoína
Isotretinoine
Isotrétinoine
Isotretinoine [INN-French]
isotretinoino
Isotretinoino
Isotretinoino [INN-Spanish]
Isotretinoinum
Isotretinoinum [INN-Latin]
Isotrex
LMPR01090021
Lopac0_001081
LS-143465
MLS001074662
MolPort-003-666-394
NCGC00094358-01
NCGC00094358-02
NCGC00094358-03
NCGC00094358-04
NCGC00094358-05
NCGC00094358-06
NCGC00094358-07
NCGC00094358-08
NCGC00094358-09
NCGC00094358-13
Neovitamin a acid
Neovitamin A acid
Prestwick_642
Prestwick2_000256
Prestwick3_000256
R 3255
R3255_SIGMA
Retinoate
Retinoic acid
Ro 4 3780
Ro 43780
Ro 4-3780
Ro-43780
Ro-4-3780
Roaccutan
Roaccutane
Roacutan
SAM002548955
SMR000471891
Sotret
Sotret (TN)
SPECTRUM1502013
Spectrum5_001795
Spectrum5_001937
Teriosal
UNII-EH28UP18IF
|
|
18 |
|
Tretinoin |
Approved, Investigational, Nutraceutical |
Phase 2 |
|
302-79-4 |
5538
444795
|
Synonyms:
(2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoate
(all-e)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate
(all-e)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
.beta.-Retinoic acid
[3H]Retinoic acid
13497-05-7 (hydrochloride salt)
15-Apo-beta-caroten-15-oic acid
187175-63-9
1n4h
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoate (ecl)
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ecl)
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ECL)
302-79-4
5300-03-8
56573-65-0
7005-78-9
9(Z)-Retinoic acid
9-cis-RA
A-Acido (Argentina)
Aberel
Aberela
Aberela [Norway]
AC1L9GWO
AC1Q1J2J
AC-6824
Accutane Roche
Acid A Vit (Belgium, Netherlands)
Acid, all-trans-retinoic
Acid, all-trans-Retinoic
Acid, beta-all-trans-retinoic
Acid, beta-all-trans-Retinoic
Acid, retinoic
Acid, Retinoic
Acid, trans-retinoic
Acid, trans-Retinoic
Acid, vitamin a
Acid, Vitamin A
Acide retinoique
Acide retinoique (French) (DSL)
Acnavit
Acnavit [Denmark]
AGN 100335
AGN 192013
Airol
Aknefug
Aknoten
AKOS000280845
Alitretinoin
all trans Retinoic acid
All Trans Retinoic Acid
all trans-Retinoic acid
All Trans-Retinoic Acid
all-(e)-Retinoate
all-(e)-Retinoic acid
all-(E)-Retinoic acid
All-trans Retinoic Acid
all-trans-beta-Retinoate
all-trans-beta-Retinoic acid
all-trans-b-Retinoate
all-trans-b-Retinoic acid
all-trans-Retinoic acid
Alltrans-retinoic acid
all-trans-Tretinoin
all-trans-Vitamin a acid
all-trans-Vitamin A acid
all-trans-Vitamin a1 acid
all-trans-Vitamin A1 acid
all-trans-β-retinoate
all-trans-β-retinoic acid
ALRT 1057
Amnesteem
ATRA
AT-RA
Atragen
Atra-IV
Atralin
Avita (TN)
Avita Gel
A-Vitaminsyre
A-Vitaminsyre [Denmark]
Avitoin
Avitoin [Norway]
BAL4079
beta all trans Retinoic acid
beta all trans Retinoic Acid
beta-all-trans-Retinoic acid
beta-Ra
beta-Retinoate
beta-Retinoic acid
beta-Retinoic Acid
Betarretin
BIDD:GT0483
BIDD:PXR0081
BML2-E05
bmse000562
BPBio1_000082
b-Retinoate
b-Retinoic acid
BRN 2057223
BSPBio_000074
BSPBio_001500
C00777
CCRIS 3294
CCRIS 7098
CHEBI:15367
CHEMBL38
CID444795
Claravis
Cordes vas
Cordes VAS [Germany]
CPD000058245
D00094
D014212
DB00523
DB00755
DB00982
Dermairol
Effederm
Effederm [France]
EINECS 206-129-0
Epi-aberel
EU-0101061
Eudyna
HMS1361K22
HMS1568D16
HMS1791K22
HMS1921D14
HMS1989K22
HMS2089D20
HMS2092N11
HMS502N05
HSDB 2169
|
HSDB 7186
I04-0008
I14-2351
IDI1_000903
IDI1_033970
Isotretinoin Retinoic acid
L000833
LGD 100057
LMPR01090019
Lopac0_001061
LS-1154
Lsotretinoin
MLS000028588
MLS001076515
MLS002207234
MLS002222211
MolPort-000-883-857
NCGC00017280-06
NCGC00017280-17
NCGC00021808-04
NCGC00021808-05
NCGC00021808-06
NCGC00021808-07
NCGC00021808-09
NCGC00021808-14
NCGC00021808-15
nchembio.154-comp2
Nexret
NSC 122758
NSC122758
NSC-122758
Panretin Gel
Panretyn
PDT-002-002
Potassium salt, tretinoin
Potassium Salt, Tretinoin
Prestwick_424
Prestwick2_000257
Prestwick3_000257
R 2625
R0064
R2625_SIGMA
REA
Renova
Renova (TN)
Retacnyl
Retin a
Retin A
Retin A (TN)
Retin-a
Retin-A
Retin-A Micro
Retinoate
Retinoic acid
RETINOIC ACID, ALL TRANS
Retinoic acid, all-trans- (8CI)
Retinova
Retionic acid
Retionic Acid
Retisol-a
Retisol-A
ro 1-5488
Ro 1-5488
S1653_Selleck
Salt, tretinoin potassium
Salt, Tretinoin Potassium
Salt, tretinoin sodium
Salt, Tretinoin Sodium
Salt, tretinoin zinc
Salt, Tretinoin Zinc
SAM002264647
SMR000058245
Sodium salt, tretinoin
Sodium Salt, Tretinoin
Solage
Sotret
SPECTRUM1502016
Spectrum5_001746
Spectrum5_001933
SR-01000000239
SR-01000000239-14
ST057075
Stieva-a
Stieva-A
Stieva-a Forte
trans Retinoic acid
trans Retinoic Acid
trans-Retinoate
trans-Retinoic acid
Tretin m
Tretin M
tretinoin
Tretinoin
Tretinoin (JAN/USP/INN)
Tretinoin (TN)
Tretinoin [USAN:INN:BAN]
Tretinoin 0.1% cream or placebo
tretinoin liposome
Tretinoin potassium salt
Tretinoin Potassium Salt
Tretinoin sodium salt
Tretinoin Sodium Salt
Tretinoin zinc salt
Tretinoin Zinc Salt
Tretinoin/All-Trans Retinoic Acid
Tretinoina
Tretinoina [INN-Spanish]
Tretinoine
Trétinoïne
tretinoine (French) (EINECS)
Tretinoine [INN-French]
Tretinoino
Tretinoino [INN-Spanish]
Tretinoinum
Tretinoinum [INN-Latin]
TRETINON
Tri-Luma
UNII-1UA8E65KDZ
UNII-5688UTC01R
UPCMLD-DP097
Vesanoid
Vesanoid (TN)
Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin
Vesnaroid
Vitamin a acid
Vitamin A acid
Vitinoin
WLN: L6UTJ A1 B1U1Y1 & U2U1Y1 & U1VQ C1 C1
WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U1VQ C1 C1
Zinc salt, tretinoin
Zinc Salt, Tretinoin
β-retinoate
β-retinoic acid
|
|
19 |
|
Vitamin D |
Approved, Nutraceutical, Vet_approved |
Phase 2 |
|
1406-16-2 |
|
Synonyms:
|
Vitamin D, unspecified form
|
|
20 |
|
Calcium |
Approved, Nutraceutical |
Phase 2 |
|
7440-70-2 |
271
|
Synonyms:
Blood coagulation factor XIII
Ca
Ca(2+)
Ca2+
Calcio
Calcium
Calcium element
CALCIUM ion
Calcium, doubly charged positive ion
Calcium, elemental
Coagulation factor XIII
Elemental calcium
Factor XIII
|
Factor XIII a chain
Factor XIII a-chain
Factor XIII transamidase
Factor XIII, coagulation
Fibrin stabilizing factor
Fibrinase
Kalzium
Laki lorand factor
Laki-lorand factor
Stabilizing factor, fibrin
Transamidase, factor XIII
XIII, coagulation factor
|
|
21 |
|
Calcitriol |
Approved, Nutraceutical |
Phase 2 |
|
32222-06-3 |
5280453
134070
|
Synonyms:
(1a,3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol
(1alpha,3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(1alpha,3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol
(1R,3S)-5-{2-[(1R,3aS,7aR)-1-((R)-5-Hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexane-1,3-diol
(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
(1S,3R,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(1S,3R,5Z,7E)-9,10-secocholesta-5,7,10-triene-1,3,25-triol
(1S,3R,5Z,7E)-9,10-Secocholesta-5,7,10-triene-1,3,25-triol
(1α,3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trienetriol
(5Z,7E)-(1S,3R)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(5Z,7E)-(1S,3R)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol
(5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1alpha,3beta,25-triol
(5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1-alpha,3-beta,25-triol
1 alpha, 25 Dihydroxy 20 epi vitamin D3
1 alpha, 25-Dihydroxy-20-epi-vitamin D3
1 alpha,25 Dihydroxycholecalciferol
1 alpha,25 Dihydroxyvitamin D3
1 alpha,25-Dihydroxycholecalciferol
1 alpha,25-Dihydroxyvitamin D3
1,25 (OH)2 D3
1,25 Dihydroxy 20 epi vitamin D3
1,25 Dihydroxycholecalciferol
1,25 Dihydroxyvitamin D3
1,25(OH)2-20epi-D3
1,25(OH)2-20EPi-D3
1,25-(OH)2D3
1,25-(OH)2-D3
1,25(OH)2D3 & CD4
1,25(OH2)D3
1,25D3
1,25-DHCC
1,25-dihydroxy vitamin D3
1,25-dihydroxy-20-epi-Vitamin D3
1,25-Dihydroxy-20-epi-vitamin D3
1,25-dihydroxycholecalciferol
1,25-Dihydroxycholecalciferol
1,25-DIHYDROXYCHOLECALCIFEROL
1,25-Dihydroxycholecaliferol
1,25-Dihydroxyvitamin D
1,25-Dihydroxyvitamin D3
1.Alpha.,25-Dihydroxy-26,27-hexadeuterovitamin D3
17936_FLUKA
17936_SIGMA
1a,25(OH)2D3
1a,25-(OH)2D3
1a,25-Dihydroxycholecalciferol
1a,25-Dihydroxyvitamin D3
1-a-25-Dihydroxyvitamin D3
1-alpha,-1,25-Dihydroxyvitamin D3
1alpha,25(OH)2D3
1alpha,25(OH)2-D3
1alpha,25-Dihydroxycholecalciferol
1-alpha,25-Dihydroxycholecalciferol
1alpha,25-Dihydroxyvitamin D
1alpha,25-Dihydroxyvitamin D3
1-alpha,25-Dihydroxyvitamin D3
1-alpha-25-dihydroxyvitamin D3
1-alpha-25-Dihydroxyvitamin D3
1db1
1α,25(OH)2D3
1α,25-dihydroxycholecalciferol
1α,25-dihydroxyvitamin D3
1-α-25-dihydroxyvitamin D3
20 Epi 1alpha,25 dihydroxycholecaliferol
20-epi-1alpha,25-dihydroxycholecaliferol
20-Epi-1alpha,25-dihydroxycholecaliferol
25-Dihydroxycholecalciferol
32222-06-3
5-{2-[1-(5-hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexane-1,3-diol
9,10-seco(5Z,7E)-5,7,10(19)-cholestatriene-1alpha, 3beta, 25-triol
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatriene-1alpha,3beta,25-triol
9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1.alpha.,3.beta,.5Z,7E)- & CD4
Abbott brand OF calcitriol
AC-1859
AC1NQX1S
alpha,25-Dihydroxyvitamin D3, 1
Alphapharm brand OF calcitriol
Ambap32222-06-3
Asentar
BCBcMAP01_000160
BML2-E03
Bocatriol
BSPBio_001287
C01673
Calcijex
Calcijex, Silkis, Rocaltrol, Topitriol, Cholecalciferol,Calcitriol
|
calcitriol
Calcitriol
Calcitriol (JAN/USAN/INN)
Calcitriol [USAN:INN:BAN:JAN]
Calcitriol abbott brand
Calcitriol alphapharm brand
Calcitriol cryopharma brand
Calcitriol galderma brand
Calcitriol gry brand
Calcitriol jenapharm brand
Calcitriol kyramed
Calcitriol kyramed brand
Calcitriol leo brand
Calcitriol medice brand
Calcitriol nefro
Calcitriol renacare brand
Calcitriol roche brand
Calcitriol-nefro
CalcitriolNefro
Calcitriolum
Calcitriolum [INN-Latin]
CCRIS 5522
CD-2027
CHEBI:17823
CHEMBL846
CID5280453
CPD000466393
Cryopharma brand OF calcitriol
D00129
D1530_SIGMA
D3, 1 alpha,25-Dihydroxyvitamin
D3, 1,25-Dihydroxy-20-epi-vitamin
D3, 1,25-Dihydroxyvitamin
Decostriol
Dihydroxyvitamin D3
DN 101
DN-101
EINECS 250-963-8
Galderma brand OF calcitriol
Gry brand OF calcitriol
HMS1361A09
HMS1791A09
HMS1989A09
HMS2051F06
HMS2089N03
Hoffmann la roche brand OF calcitriol
Hoffmann-la roche brand OF calcitriol
HSDB 3482
IDI1_033757
Jenapharm brand OF calcitriol
KyraMed brand OF calcitriol
KyraMed, calcitriol
leo Brand OF calcitriol
LMST03020258
LS-53093
MC1288
MC-1288
Medice brand OF calcitriol
MLS000759536
MLS001424122
MolPort-002-045-698
NCGC00161327-01
NCGC00161327-04
Osteotriol
RenaCare brand OF calcitriol
Renatriol
ro 21-5535
Ro 215535
Ro 21-5535
Ro-21-5535
Rocaltrol
Rocaltrol (TN)
Roche brand OF calcitriol
S1466_Selleck
SAM001246772
Silkis
Sitriol
SMR000466393
Soltriol
Spectrum5_002061
Tirocal
Topitriol
Toptriol
U 49562
Vectical
vit D
ZINC03924790
|
|
22 |
|
Anti-Infective Agents |
|
Phase 2 |
|
|
|
23 |
|
Pharmaceutical Solutions |
|
Phase 2 |
|
|
|
24 |
|
insulin |
|
Phase 2 |
|
|
|
25 |
|
Insulin, Globin Zinc |
|
Phase 2 |
|
|
|
26 |
|
Mitogens |
|
Phase 2 |
|
|
|
27 |
|
Hypoglycemic Agents |
|
Phase 2 |
|
|
|
28 |
|
Hormone Antagonists |
|
Phase 2 |
|
|
|
29 |
|
Hormones, Hormone Substitutes, and Hormone Antagonists |
|
Phase 2 |
|
|
|
30 |
|
Oxytocics |
|
Phase 2 |
|
|
|
31 |
|
Hormones |
|
Phase 2 |
|
|
|
32 |
|
Micronutrients |
|
Phase 2 |
|
|
|
33 |
|
Trace Elements |
|
Phase 2 |
|
|
|
34 |
|
Dihydroxycholecalciferols |
|
Phase 2 |
|
|
|
35 |
|
Vitamins |
|
Phase 2 |
|
|
|
36 |
|
Nutrients |
|
Phase 2 |
|
|
|
37 |
|
Keratolytic Agents |
|
Phase 2 |
|
|
|
38 |
|
Dermatologic Agents |
|
Phase 2 |
|
|
|
39 |
|
Vasoconstrictor Agents |
|
Phase 2 |
|
|
|
40 |
|
Calciferol |
|
Phase 2 |
|
|
|
41 |
|
Calcium, Dietary |
|
Phase 2 |
|
|
|
42 |
|
Bone Density Conservation Agents |
|
Phase 2 |
|
|
|
43 |
|
Melatonin |
Approved, Nutraceutical, Vet_approved |
Phase 1 |
|
73-31-4 |
896
|
Synonyms:
{N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-} acetamide
{N-[2-(5-methoxyindol-3-yl)ethyl]-} acetamide
0E2B08C1-B325-45B1-8939-6F9081EFDFA4
4-ACETAMIDO-4'-ISOTHIO-CYANATOSTILBENE-2,2'-DISULFONIC ACID
5-22-12-00042 (Beilstein Handbook Reference)
5-methoxy-N-acetyltryptamine
5-Methoxy-N-acetyltryptamine
73-31-4
A4039/0172195
AB00053279
AC1L1A9Q
AC1Q4F1W
AC1Q4F1X
Acetamide, {N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-}
Acetamide, {N-[2-(5-methoxyindol-3-yl)ethyl]-}
Acetamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)- (9CI)
Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]- (9CI)
Acetamide, N-[2-(5-methoxyindol-3-yl)ethyl]- (6CI,8CI)
AKOS000276269
BAS 01281092
BIDD:ER0618
Bio-0635
BPBio1_000590
BRD-K97530723-001-07-6
BRN 0205542
BSPBio_000536
BSPBio_003006
C01598
CAS-73-31-4
CCRIS 3472
CHEBI:16796
CHEMBL45
ChemDiv2_003916
CID896
Circadin
D008550
D08170
DB01065
DB08189
DivK1c_000353
EINECS 200-797-7
EU-0100787
HMS1380B22
HMS1569K18
HMS1921E04
HMS2089F09
HMS501B15
HSCI1_000400
HSDB 7509
I05-0076
I10-0345
IDI1_000353
IDI1_002631
IN1244
KBio1_000353
KBio2_000665
KBio2_003233
KBio2_005801
KBio3_002226
KBioGR_000591
KBioSS_000665
L001261
Lopac0_000787
Lopac-M-5250
LS-1623
M 5250
M1105
M-1200
M-1250
M5250_SIGMA
Melapure
Mela-T
Melatol
Melatonex
Melatonex, Melatonin
Melatonin
Melatonin (synth.) standard-grade
Melatonin (synth.) ultra-pure
Melatonina
Melatonina (TN)
Melatonine
|
Mélatonine
Melovine
ML1
MLS000859594
MLS001055382
MLS001240204
MolPort-000-737-883
MT6
N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)-acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]-acetamide
N-[2-(5-methoxyindol-3-yl)ethyl]acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]-acetamide
N-acetyl-5-methoxy-tryptamine
N-Acetyl-5-methoxytryptamine
N-Acetyl-5-methoxy-tryptamine
N-Acetyl-5-methoxy-tryptamine melatonine
Nature'S Harmony
NCGC00015680-01
NCGC00015680-02
NCGC00015680-03
NCGC00015680-06
NCGC00015680-13
NCGC00090727-01
NCGC00090727-02
NCGC00090727-03
NCGC00090727-04
NCGC00090727-05
NCGC00090727-06
NCGC00090727-07
NCGC00090727-08
NCGC00090727-09
NCI60_004378
Night Rest
NINDS_000353
NMR/14327425
NSC 113928
NSC113928
NSC56423
Oprea1_104553
Oprea1_814234
Pineal Hormone
Posidorm
Prestwick_312
Prestwick0_000458
Prestwick1_000458
Prestwick2_000458
Prestwick3_000458
PREVENTION 1 (MELATONIN) (PREVENTION 1)
PREVENTION 2 (MELATONIN)
PREVENTION 3 (MELATONIN)
PREVENTION 4 (MELATONIN)
PREVENTION 5 (MELATONIN)
Regulin
Revital Melatonin
Rx Balance
S1204_Selleck
SDCCGMLS-0065812.P001
SDCCGMLS-0065812.P002
Sleep Right
SMP2_000309
SMR000326666
SPBio_001527
SPBio_002475
Spectrum_000185
SPECTRUM1500690
Spectrum2_001344
Spectrum3_001393
Spectrum4_000066
Spectrum5_001745
STK386880
TNP00300
UNII-JL5DK93RCL
Vivitas
WLN: T56 BMJ D2MV1 GO1
ZINC00057060
|
|
44 |
|
Antioxidants |
|
Phase 1 |
|
|
|
45 |
|
Central Nervous System Depressants |
|
Phase 1 |
|
|
|
46 |
|
Protective Agents |
|
Phase 1 |
|
|
|
47 |
|
Anesthetics |
|
|
|
|
|
48 |
|
Hemostatics |
|
|
|
|
|
Interventional clinical trials:
(show all 18)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Prevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos Syndrome |
Completed |
NCT00190411
|
Phase 4 |
celiprolol;Control |
2 |
Sulfamethoxazole for the Treatment of Primary PREPL Deficiency (In Dutch: Sulfamethoxazole Ter Behandeling Van Primaire PREPL deficiëntie) |
Unknown status |
NCT02640443
|
Phase 2 |
Sulfamethoxazole |
3 |
A Double-Blind Placebo-Controlled Crossover Trial of Insulin-Like Growth Factor-1 (IGF-1) in Children and Adolescents With 22q13 Deletion Syndrome(Phelan-McDermid Syndrome) |
Recruiting |
NCT01525901
|
Phase 2 |
Insulin-Like Growth Factor-1 (IGF-1);Normal saline |
4 |
An Open Label Trial of Growth Hormone in Children and Adolescents With Phelan-McDermid Syndrome Targeting Social Withdrawal |
Recruiting |
NCT04003207
|
Phase 2 |
Recombinant human Growth hormone |
5 |
Piloting Treatment With Intranasal Oxytocin in Phelan-McDermid Syndrome |
Recruiting |
NCT02710084
|
Phase 2 |
Oxytocin;Saline |
6 |
An Open-label Study to Investigate the Safety, Tolerability and Efficacy of a Single 6-hour Intravenous Infusion of AMO-01 to Treat Adolescents and Adults With Phelan-McDermid Syndrome (PMS) and Co-morbid Epilepsy |
Recruiting |
NCT03493607
|
Phase 2 |
AMO-01 |
7 |
A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder |
Recruiting |
NCT01970345
|
Phase 2 |
IGF-1;Placebo/saline |
8 |
A Pilot Trial of 13-cis Retinoic Acid (Isotretinoin) for the Treatment of Men With Oligoasthenoteratozoospermia |
Active, not recruiting |
NCT02061384
|
Phase 2 |
13-cis retinoic acid;Calcitriol |
9 |
A Phase One Treatment Trial of the Circadian Sleep Disturbance in Smith-Magenis Syndrome (SMS) |
Completed |
NCT00506259
|
Phase 1 |
dTR Melatonin (NIH CC PDS);Melatonin CR |
10 |
PREPL in Health and Disease |
Unknown status |
NCT02263781
|
|
|
11 |
Mitochondrial Dysfunction in Phelan-McDermid Syndrome: Explaining Clinical Variation and Providing a Path Towards Treatment |
Completed |
NCT02000167
|
|
|
12 |
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women |
Completed |
NCT02787486
|
|
|
13 |
Study of the Pathophysiological Mechanisms Involved in Bleeding Events Observed in Patients With Lowe Syndrome |
Completed |
NCT01314560
|
|
|
14 |
Mapping the Phenotype in Adults With Phelan-McDermid Syndrome |
Recruiting |
NCT03426059
|
|
|
15 |
Behavioral, Molecular and Genetic Characterization of 3q29 Deletion Syndrome and 3q29 Duplication Syndrome |
Recruiting |
NCT02447861
|
|
|
16 |
Coordination of Rare Diseases at Sanford |
Recruiting |
NCT01793168
|
|
|
17 |
Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome |
Active, not recruiting |
NCT02461420
|
|
|
18 |
Impact of Y-chromosome Microdeletions From Infertile Men on the Chromosomal Constitution of Their Spermatozoa and Embryos. Combined IntraCytoplasmatic Sperm Injection (ICSI) and Preimplantation Genetic Screening (PGS) as Treatment Strategy. |
Terminated |
NCT02527954
|
|
|
|